2019年2期
Cancer Drug Resistance
Review
- Drug resistance and combating drug resistance in cancer
- Emerging targets in cancer drug resistance
- Mechanism of resistance to immune checkpoint inhibitors
- Molecular mechanisms of enzalutamide resistance in prostate cancer
- New insights into acquired endocrine resistance of breast cancer
- Overcome cancer drug resistance by targeting epigenetic modifications of centrosome
- Pharmacogenetic and pharmacogenomic discovery strategies
- Pharmacogenetics of asparaginase in acute lymphoblastic leukemia
- Pharmacogenetics of thiopurines
- Resistance to cis- and carboplatin initiated by epigenetic changes in ovarian cancer patients
- Role of cellular reprogramming and epigenetic dysregulation in acquired chemoresistance in breast cancer
- The epigenome in pediatric acute lymphoblastic leukemia:drug resistance and therapeutic opportunities
- The role of histone lysine demethylases in cancer cells' resistance to tyrosine kinase inhibitors